Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ORGO
SellUnloved QualityOrganogenesis Holdings Inc. · Healthcare · United States · $224M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing, manufacturing, and commercializing advanced wound care and surgical biologics products. Its competitive advantage stems from proprietary, clinically proven bioengineered tissue technologies and a strong sales force serving the growing market for chronic and complex wounds. The company is a key innovator in the field of tissue regeneration.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 450.9M | 433.1M | 482.0M | 563.0M | 7.7% | 457.5M | 196.1M | 269.7M | -30.8% |
| EPS | 0.12 | 0.04 | -0.01 | 0.16 | 10.1% | -0.79 | -1.38 | -0.31 | — |
| Shares | 130.9M | 131.3M | 125.7M | 127.0M | -3.0% | 128.7M | — | — | — |
| Debt | 123.8M | 119.4M | 43.3M | 82.1M | -12.8% | 67.0M | — | — | — |
| Equity | 265.7M | 278.7M | 385.3M | 433.9M | 17.8% | — | — | — | — |
| Op CF | 24.9M | 30.9M | 14.2M | -10.3M | -24.4% | 32.0M | — | — | — |
| Inv CF | -33.9M | -24.4M | -10.0M | -14.2M | — | — | — | — | — |
| Fin CF | -2.2M | -5.5M | 27.6M | -17.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORGO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ORGO | Organogenesis Holdings Inc.(you) | $224M | 29 | Sell |
| SIGA | SIGA Technologies, Inc. | $220M | 30 | Sell |
| DERM | Journey Medical Corporation | $211M | 24 | Sell |
| AKBA | Akebia Therapeutics, Inc. | $243M | 17 | Strong Sell |
| LFCR | Lifecore Biomedical, Inc. | $172M | 16 | Strong Sell |
| CL.CN | Cresco Labs Inc. | $291M | 43 | Hold |
| CPIX | Cumberland Pharmaceuticals Inc. | $127M | 38 | Hold |
| VREO.CN | Vireo Growth Inc. | $552M | 33 | Sell |
| TKNO | Alpha Teknova, Inc. | $382M | 44 | Hold |
| JUSH.CN | Jushi Holdings Inc. | $110M | 43 | Hold |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%